Compare PMAX & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMAX | PMCB |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 5.3M |
| IPO Year | 2024 | N/A |
| Metric | PMAX | PMCB |
|---|---|---|
| Price | $2.65 | $1.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.7M | ★ 9.7M |
| Earning Date | 09-23-2025 | 12-15-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $4,799,100.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $182.71 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.56 | $0.63 |
| 52 Week High | $25.12 | $1.90 |
| Indicator | PMAX | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 59.40 | 59.86 |
| Support Level | $2.54 | $0.71 |
| Resistance Level | $3.35 | $1.51 |
| Average True Range (ATR) | 0.33 | 0.19 |
| MACD | 0.10 | 0.05 |
| Stochastic Oscillator | 67.60 | 49.06 |
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.